This Biotech ETF Is “Prime Hunting Ground” For Big Pharma Companies Looking For Takeover Targets

Industry analysts expect M&A activity in the biotech space to accelerate in the back half of 2021 – and that could drive the ETF highlighted in today’s article higher, as the author notes that “few biotech ETFs can rival [this fund] when it comes to holdings being the subjects of buyout rumors or becoming actual takeover targets.” For more on this ETF that’s “prime hunting ground” for big pharma companies looking for takeover targets – and some specific holdings that analysts see as credible targets – CLICK HERE.